Amyl Therapeutics is a preclinical biotechnology company developing immunotherapy for neurodegenerative diseases.
Amyl Therapeutics has raised $9.6M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Amyl Therapeutics's investors include Mérieux Equity Partners, Sambrinvest, Meusinvest (Noshaq), Evren Ucok, Smedvig.
Amyl Therapeutics is headquartered in Liège, Belgium.
Amyl Therapeutics is a preclinical biotechnology company developing immunotherapy for neurodegenerative diseases.
Amyl Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amyl Therapeutics — Funding & Investors." VCBacked, September 1, 2026, https://www.vcbacked.co/company/amyl-therapeutics. Accessed October 3, 2026.
VCBacked. (2026). Amyl Therapeutics — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/amyl-therapeutics
{{cite web |title=Amyl Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amyl-therapeutics |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated